Literature DB >> 8462365

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

A Wettergren1, B Schjoldager, P E Mortensen, J Myhre, J Christiansen, J J Holst.   

Abstract

We studied the effect of intravenous infusion of synthetic truncated GLP-1 (proglucagon 78-107-amide) on fasting and postprandial gastric acid secretion, gastric emptying, and pancreatic secretion of trypsin and lipase in eight normal volunteers using marker dilution and aspiration technique. The infusion resulted in a plasma concentration of 110 +/- 14 pmol/liter (mean +/- SEM). Truncated GLP-1 significantly inhibited postprandial acid secretion by 43 +/- 11% in spite of unchanged plasma gastrin concentration. Gastric emptying rate decreased significantly; 50% emptying time increased from 16 +/- 2 min to 30 +/- 5 min. Postprandial trypsin and lipase outputs were significantly inhibited by 47 +/- 17% and 40 +/- 9% during truncated GLP-1 infusion. Pancreatic enzyme output was linearly correlated to gastric emptying, and truncated GLP-1 did not affect this relationship, suggesting that the effect on pancreatic secretion was secondary to the effect on gastric emptying. Postprandial insulin and glucagon concentrations were similar with and without truncated GLP-1 infusion in spite of significantly lower blood glucose levels (5.2 +/- 0.2 versus 3.7 +/- 0.3), indicating that GLP-1 stimulated insulin secretion and inhibited glucagon secretion. In conclusion, our results suggest that truncated GLP-1 act as a physiological inhibitor of gastric and pancreatic functions in man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8462365     DOI: 10.1007/bf01316798

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  28 in total

1.  Measurement of gastric functions during digestion of ordinary solid meals in man.

Authors:  J R Malagelada; G F Longstreth; W H Summerskill; V L Go
Journal:  Gastroenterology       Date:  1976-02       Impact factor: 22.682

2.  GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.

Authors:  B T Schjoldager; P E Mortensen; J Christiansen; C Orskov; J J Holst
Journal:  Dig Dis Sci       Date:  1989-05       Impact factor: 3.199

3.  Determination of serum or plasma glucose on the "AutoAnalyzer II" by use of the hexokinase reaction.

Authors:  G M Widdowson; J R Penton
Journal:  Clin Chem       Date:  1972-03       Impact factor: 8.327

4.  Simultaneous measurements of total pancreatic, biliary, and gastric outputs in man using a perfusion technique.

Authors:  V L Go; A F Hofmann; W H Summerskill
Journal:  Gastroenterology       Date:  1970-03       Impact factor: 22.682

5.  Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man.

Authors:  D J O'Halloran; G C Nikou; B Kreymann; M A Ghatei; S R Bloom
Journal:  J Endocrinol       Date:  1990-07       Impact factor: 4.286

6.  Inhibition of gastric acid secretion in man by exogenous and endogenous pancreatic glucagon.

Authors:  J Christiansen; J J Holst; E Kalaja
Journal:  Gastroenterology       Date:  1976-05       Impact factor: 22.682

7.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

Authors:  S Mojsov; G Heinrich; I B Wilson; M Ravazzola; L Orci; J F Habener
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

8.  Effect of peptide YY on gastric, pancreatic, and biliary function in humans.

Authors:  T E Adrian; A P Savage; G R Sagor; J M Allen; A J Bacarese-Hamilton; K Tatemoto; J M Polak; S R Bloom
Journal:  Gastroenterology       Date:  1985-09       Impact factor: 22.682

9.  Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut.

Authors:  G Böttcher; K Sjölund; E Ekblad; R Håkanson; T W Schwartz; F Sundler
Journal:  Regul Pept       Date:  1984-07

10.  Identical mRNA for preproglucagon in pancreas and gut.

Authors:  U Novak; A Wilks; G Buell; S McEwen
Journal:  Eur J Biochem       Date:  1987-05-04
View more
  132 in total

1.  Effect of exogenous insulin and glucagon on exocrine pancreatic secretion in rats in vivo.

Authors:  R Ferrer; J Medrano; M Diego; R Calpena; L Graells; M Moltó; T Pérez; F Pérez; G Salido
Journal:  Int J Pancreatol       Date:  2000-08

2.  Truncated and full-length glucagon-like peptide-1 (GLP-1) differentially stimulate intestinal somatostatin release.

Authors:  P L Brubaker; S Efendic; G R Greenberg
Journal:  Endocrine       Date:  1997-02       Impact factor: 3.633

3.  Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

Authors:  Sara Baldassano; Guo-Du Wang; Flavia Mulè; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-10       Impact factor: 4.052

4.  Circulating GLP-1 and CCK-8 reduce food intake by capsaicin-insensitive, nonvagal mechanisms.

Authors:  Jingchuan Zhang; Robert C Ritter
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-26       Impact factor: 3.619

Review 5.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

6.  The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.

Authors:  R J Mann; N E Nasr; J K Sinfield; E Paci; D Donnelly
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 7.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

8.  Forebrain and hindbrain effects of ethanol on counterregulatory responses to hypoglycemia in conscious rats.

Authors:  Darleen A Sandoval; Bin Gong; Stephen N Davis
Journal:  Metabolism       Date:  2007-12       Impact factor: 8.694

9.  Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Authors:  T Tolessa; M Gutniak; J J Holst; S Efendic; P M Hellström
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

10.  Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice.

Authors:  Gunnar Sørensen; S Barak Caine; Morgane Thomsen
Journal:  Alcohol Clin Exp Res       Date:  2016-08-31       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.